Opus Genetics (IRD) Total Non-Current Liabilities (2010 - 2026)
Opus Genetics (IRD) posted quarterly Total Non-Current Liabilities of $10.5 million for Q1 2026, down 56.55% year-over-year from $24.3 million in Q1 2025, and up 18.27% quarter-over-quarter from $8.9 million in Q4 2025.
Opus Genetics (IRD) Total Non-Current Liabilities (2010 - 2026) Analysis & Trends
Opus Genetics (IRD) has reported Total Non-Current Liabilities for 17 consecutive years, with $10.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Non-Current Liabilities fell 56.55% year-over-year to $10.5 million; the TTM figure through Mar 2026 stood at $10.5 million (down 56.55% YoY), while the FY2025 annual figure was $8.9 million, down 21.12% from the prior year.
- Total Non-Current Liabilities climbed to $10.5 million in Q1 2026 per IRD's latest filing, from $8.9 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $30.2 million in Q3 2025 and bottomed at $2.7 million in Q3 2022.
- Historically, Total Non-Current Liabilities has averaged $8.9 million across 5 years, with a median of $5.7 million in 2023.
- Annual changes were most pronounced in 2025 — Total Non-Current Liabilities jumped 404.81% — and 2026, when it sank 56.55%.
- Opus Genetics' Total Non-Current Liabilities stood at $2.8 million in 2022, then surged by 45.91% to $4.0 million in 2023, then surged by 181.18% to $11.3 million in 2024, then dropped by 21.12% to $8.9 million in 2025, then rose by 18.27% to $10.5 million in 2026.
- Business Quant data shows IRD's Total Non-Current Liabilities at $10.5 million in Q1 2026, $8.9 million in Q4 2025, and $30.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Opus Genetics | 298.36 Mn | 209.55 Mn | - | 43.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 43.81 Mn |
| Mar 31, 2026 | 10.54 Mn |
| Dec 31, 2025 | 8.91 Mn |
| Sep 30, 2025 | 30.16 Mn |
| Jun 30, 2025 | 21.19 Mn |
| Mar 31, 2025 | 24.25 Mn |
| Dec 31, 2024 | 11.30 Mn |
| Sep 30, 2024 | 6.09 Mn |
| Jun 30, 2024 | 4.20 Mn |
| Mar 31, 2024 | 5.79 Mn |
| Dec 31, 2023 | 4.02 Mn |
| Sep 30, 2023 | 3.82 Mn |
| Jun 30, 2023 | 5.68 Mn |
| Mar 31, 2023 | 4.15 Mn |
| Dec 31, 2022 | 2.75 Mn |
| Sep 30, 2022 | 2.69 Mn |
| Jun 30, 2022 | 3.30 Mn |
| Mar 31, 2022 | 3.21 Mn |
| Dec 31, 2021 | 3.86 Mn |
| Sep 30, 2021 | 2.64 Mn |